Posted by Michael Wonder on 05 Sep 2018
Health Canada approves Perjeta (pertuzumab) for the treatment of HER2 positive early breast cancer after surgery
4 September 2018 - New treatment option can significantly reduce risk of disease recurrence or death, preventing breast cancer from returning and progressing to an incurable stage.
Roche Canada announced today that Health Canada has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment of patients with human epidermal growth factor receptor 2 positive early breast cancer (eBC) with lymph node positive and/or hormone receptor negative disease.
This adjuvant Perjeta-based regimen should be administered for a total of one year (maximum 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first) as part of a complete regimen for eBC.
